Similar articles

• ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit.

  Newman G. Newman G. Lancet. 2003 Oct 18;362(9392):1333; author reply 1334. doi: 10.1016/S0140-6736(03)14602-8. Lancet. 2003. PMID: 14575996 No abstract available.
• ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit.

  Wheatley K, Gray R. Wheatley K, et al. Lancet. 2003 Oct 18;362(9392):1333; author reply 1334. doi: 10.1016/S0140-6736(03)14601-6. Lancet. 2003. PMID: 14575997 No abstract available.
• Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

  Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M. Oza AM, et al. Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4. Lancet Oncol. 2015. PMID: 25481791 Clinical Trial.
• Current status of taxane and platinum-based chemotherapy in ovarian cancer.

  McGuire WP 3rd. McGuire WP 3rd. J Clin Oncol. 2003 May 15;21(10 Suppl):133s-135s. doi: 10.1200/JCO.2003.01.066. J Clin Oncol. 2003. PMID: 12743128 Review.
• Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer.

  Muggia FM. Muggia FM. Semin Oncol. 2004 Dec;31(6 Suppl 15):19-24. doi: 10.1053/j.seminoncol.2004.11.024. Semin Oncol. 2004. PMID: 15726535 Review.